Mundipharma’s Pelmeg now available in Europe

Mundipharma received European Commission approval for Pelmeg (pegfilgrastim), a biosimilar of Neulasta, in November 2018, based on regulatory submission of biofunctional, analytical, preclinical and clinical studies to demonstrate biosimilarity in terms of its efficacy, quality and safety. The company has now launched Pelmeg, its fourth biosimilar medicine, in Holland, Germany and Ireland, where it is indicated for the reduction of the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (apart from chronic myeloid leukaemia and myelodysplastic syndromes).
Philippe Bastide, head of biosimilars, Europe, said: “We are delighted that Pelmeg is now available in these countries. The launch of the treatment builds on our proven commercial excellence in biosimilars over the past four years. Pelmeg has the potential to play an important role in improving the lives of patients affected by chemotherapy induced neutropenia and febrile neutropenia. Through our partnership with Celltrion, we estimate Remsima and Truxima have already saved European healthcare systems approximately €330m. If all patients currently being treated with the reference product are offered access to Pelmeg, further significant savings can be realised for the healthcare community.”